Welcome to our dedicated page for Scienture Holdings SEC filings (Ticker: SCNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scienture Holdings, Inc. (NASDAQ: SCNX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy materials and registration-related documents. Scienture files with the U.S. Securities and Exchange Commission as a Delaware corporation under Commission File Number 001-39199, and its filings offer detailed insight into its specialty pharmaceutical business conducted through its wholly owned subsidiary, Scienture, LLC.
Among the most informative documents for SCNX are current reports on Form 8-K, which describe material events such as financing arrangements, amendments to debt agreements, conversion of secured convertible debentures into common stock, and the issuance of senior secured promissory notes. These filings outline key terms such as principal amounts, original issue discounts, interest rates, security agreements granting liens on company and subsidiary assets, and guaranty obligations. Other 8-Ks address corporate actions including amendments to bylaws, notices from Nasdaq regarding minimum bid price compliance, and results of stockholder votes at the annual meeting.
Scienture’s definitive proxy statement on Schedule 14A is another core filing, setting out proposals submitted to stockholders, including director elections, potential increases in authorized share capital, amendments to the company’s equity incentive plan, authorization for a potential future offering of common stock under Nasdaq Listing Rule 5635(d), and possible reverse stock split authority. The proxy statement also explains governance structures, committee charters and procedures for the annual meeting.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex topics such as capital structure changes, equity distribution agreements on Form S-3, or listing compliance matters. Users can review historical and recent filings, monitor how Scienture manages its financing and governance, and reference official disclosures related to its specialty products, including Arbli™ and REZENOPY™. This page is a resource for investors seeking structured, regulator-reviewed information on SCNX beyond press releases and market commentary.
Scienture Holdings, Inc. reported that its Chief Financial Officer, Eric Sherb, resigned effective May 26, 2026. He informed the company that he was leaving for personal reasons and that his decision was not related to any dispute or disagreement with management or the board.
On the same date, the company appointed Dr. Narasimhan Mani, age 51, as Interim Chief Financial Officer. Dr. Mani already serves as Co-Chief Executive Officer, President, and a director, and has been overseeing operations including financial planning, revenue and expense management, and financial reporting.
The disclosure highlights Dr. Mani’s more than 25 years of pharmaceutical industry experience, his prior senior roles at several life sciences companies, and his advanced degrees including an MBA in Finance and Marketing from Columbia Business School. His service as Interim CFO will continue under his existing employment agreement previously filed with the SEC.
Scienture Holdings, Inc. reported very early-stage commercial results for the quarter ended March 31, 2026. Revenue rose to about $56 thousand, up roughly 449% from the prior-year quarter, as sales of its SCN-102/Arbli losartan oral suspension ramped.
Gross profit increased to about $54 thousand and gross margin expanded sharply to roughly 95.6%, while total operating expenses stayed roughly flat at about $3.56 million. The company posted a net loss of about $3.4 million, slightly higher than a year earlier.
Operationally, Scienture highlighted new patent protection for Arbli, an Orange Book–listable patent for REZENOPY 10 mg naloxone nasal spray, expanded GPO agreements giving REZENOPY access to over 5,000 healthcare institutions, and an additional $11.0 million in non-dilutive debt financing to support commercialization and its R&D pipeline.
Scienture Holdings, Inc. posted modest early commercialization revenue while continuing to generate sizable losses in the quarter ended March 31, 2026. Revenue rose to $56,325, driven entirely by initial sales of ARBLI™ (SCN-102), but the company recorded a net loss of $3.4 million and an operating loss of $3.5 million.
Cash and cash equivalents were $3.54 million with positive working capital of about $1.97 million, versus an accumulated deficit of $83.95 million. Intangible assets tied to the Scienture pipeline totaled roughly $70.5 million after prior impairments, with SCN-102 now amortizing over 13 years.
Management highlights substantial doubt about the company’s ability to continue as a going concern, relying on ARBLI™ commercialization, tight cost control, and access to additional capital. After quarter-end, Scienture entered into new secured Streeterville notes totaling $11.42 million, funding $8.0 million immediately and placing $3.0 million in a controlled account, secured by substantially all assets.
Scienture Holdings, Inc. furnished an updated investor presentation on its website on May 5, 2026 and attached it as Exhibit 99.1 to this report. The presentation is intended for meetings with analysts, potential investors, and other interested parties and should be read together with the company’s SEC filings.
The material in the presentation and this report is furnished under Regulation FD, is not deemed “filed,” and is not incorporated into other SEC filings unless specifically referenced. Scienture also includes typical cautionary language about forward-looking statements and refers readers to risk discussions in its Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Scienture Holdings, Inc. entered into and closed a note purchase agreement with Streeterville Capital, LLC, issuing two secured promissory notes: a Secured Promissory Note A-1 with an original principal amount of $8.42 million and a Secured Promissory Note B with an original principal amount of $3 million.
The A-1 Note carries a $400,000 original issue discount and $20,000 in transaction costs, bears 9% annual interest and matures in eighteen months; the Lender funded $8 million at closing. The B Note bears 5% annual interest, matures in eighteen months, and $3 million was deposited into a controlled account of a newly formed subsidiary under a Deposit Account Control Agreement.
Both notes are secured by security agreements, a guaranty, and a pledge of subsidiary equity, contain detailed Major and Minor Trigger Events that can increase outstanding balances by up to 25%, and allow Monthly Redemptions up to $175,000 and Limited Redemptions tied to trading volume and price conditions.
Scienture Holdings, Inc. files an amended annual report that keeps 2025 results and governance details together in one place while correcting immaterial MD&A errors and adding Part III information. For 2025, the company generated revenue of $431,609, mainly from initial ARBLI™ sales, but recorded a net loss of $41,512,264 driven by $26,346,050 of non-cash impairment charges and higher financing costs.
Cash and cash equivalents were $6,662,008 as of December 31, 2025, with positive working capital of approximately $5,181,000, and management concluded there is no substantial doubt about the company’s ability to continue as a going concern for at least twelve months. Operations are being refocused on Scienture LLC’s branded and specialty pharmaceutical pipeline, funded in part by approximately $26,293,039 of 2025 equity proceeds and divestitures of legacy businesses.
Scienture Holdings, Inc. files its annual report describing a transition into a commercial-stage specialty pharmaceutical company focused on cardiovascular and central nervous system diseases. The company reports an aggregate public float of about $10.2 million and 40,630,815 common shares outstanding as of March 27, 2026.
Subsidiary Scienture LLC leads the business, with its first FDA‑approved product, SCN‑102 losartan potassium oral suspension 10 mg/mL, launched in 2025 as the first approved liquid losartan formulation. It also licensed and will commercialize a high‑dose 10 mg naloxone nasal spray (REZENOPY) under an exclusive U.S. agreement with Kindeva.
The filing outlines a pipeline including SCN‑104 (multi‑dose DHE injection pen for migraine), SCN‑106 (potential Cathflo biosimilar for thrombotic catheter occlusion) and SCN‑107 (long‑acting bupivacaine for post‑surgical pain), supported by multiple IP filings and licensing deals. Extensive risk disclosures highlight funding needs, going‑concern uncertainty, regulatory and IP challenges, Nasdaq listing risks, potential dilution, and high stock price volatility.
Scienture Holdings Co-CEO & Chairman Dr. Shankar Hariharan reported several stock acquisitions and conversions, mainly as equity compensation and prior preferred stock conversions. On February 20, 2026, he was approved for an award of 500,000 restricted shares as a discretionary stock bonus for 2025, to be issued in three tranches of 166,666, 166,667, and 166,667 shares on June 1, September 1, and December 1, 2026, with each tranche vesting three years after issuance. Earlier, he received 750,000 restricted shares on April 14, 2025 and 300,000 restricted shares on October 1, 2025, each vesting in two equal annual installments beginning April 14, 2026 and October 1, 2026, respectively. The filing also shows that on September 19, 2024, his and his spouse’s Series X Non-Voting Convertible Preferred Stock automatically converted into a total of 2,272,296 common shares. In a separate non-market transaction, 30,000 common shares were transferred to a designee of NVK Finance, LLC as consideration for the lender’s consent under a loan amendment. Following the latest award, he directly holds 3,518,679 common shares.
Scienture Holdings, Inc. President & Co-CEO Narasimhan Mani reported multiple equity awards and a prior conversion transaction. On February 20, 2026, the board’s Compensation Committee approved an award of 500,000 restricted common shares as a discretionary stock bonus for 2025 performance, to be issued in three tranches during 2026 and each tranche vesting three years after issuance. Following this award, he holds 1,550,000 common shares directly.
Earlier, he received 750,000 restricted shares on April 14, 2025 and 300,000 restricted shares on October 1, 2025, each vesting in two equal annual installments beginning in 2026. An entity associated with him, Srivatsav, LLC, converted 1,357,538 shares of Series X Non-Voting Convertible Preferred Stock into common stock on September 19, 2024, and later transferred 20,000 common shares to a designee of NVK Finance, LLC as consideration for the lender’s consent to an amended loan agreement.
Scienture Holdings, Inc. (SCNX) announced that it has posted a revised investor presentation on its website and plans to use it in meetings with analysts, potential investors, and other interested parties. The presentation, attached as Exhibit 99.1, provides summary information about the company that should be read together with its reports filed with the SEC.
The company emphasizes that the materials are furnished under Regulation FD, not filed, meaning they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings. The presentation includes forward-looking statements about projects, potential financial performance, and growth opportunities, and the company reminds readers that actual results may differ due to various risks described in its latest Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q.